Products
Vepsitamab Biosimilar Bispecific scFv-Fc Antibody (MUC17 × CD3) for Research
Cat No.: GMP-Bios-ab-708
Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-708-1mg | 1mg | |
| GMP-Bios-ab-708-10mg | 10mg | |
| GMP-Bios-ab-708-100mg | 100mg | |
| GMP-Bios-ab-708-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody |
| INN Name | Vepsitamab |
| Target | MUC17;CD3E |
| Format | Bispecific scFv-scFv-scFc |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | na;na |
| VD LC | Lambda;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2021 |
| Year Recommended | na |
| Companies | Amgen |
| Conditions Approved | na |
| Conditions Active | GE Junction Cancer;Gastric Adenocarcinoma |
| Conditions Discontinued | na |
| Development Tech | BiTE Technology |
